Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: A multicenter randomized controlled trial

Background We evaluated the efficacy of tailored therapy based on point mutation presence identified with the dual‐priming oligonucleotide (DPO)‐based multiplex polymerase chain reaction (PCR) method compared with concomitant therapy. Materials and methods Subjects were randomly assigned concomitant...

Full description

Saved in:
Bibliographic Details
Published in:Helicobacter (Cambridge, Mass.) Mass.), 2019-10, Vol.24 (5), p.e12654-n/a
Main Authors: Ong, Sungmoon, Kim, Sung Eun, Kim, Ji Hyun, Yi, Nam Hee, Kim, Tae Young, Jung, Kyoungwon, Park, Moo In, Jung, Hwoon‐Yong
Format: Article
Language:English
Subjects:
Aged
Amoxicillin
Anti-Bacterial Agents - administration & dosage
Clarithromycin
concomitant therapy
Drug Resistance, Bacterial
Eradication
Female
Helicobacter Infections - drug therapy
Helicobacter Infections - microbiology
Helicobacter pylori
Helicobacter pylori - genetics
Helicobacter pylori - isolation & purification
Humans
Male
Metronidazole
Microbial Sensitivity Tests - methods
Middle Aged
Molecular Diagnostic Techniques - methods
Multiplex Polymerase Chain Reaction - methods
Multiplexing
Mutation
Oligonucleotides
Point Mutation
Polymerase chain reaction
Precision Medicine - methods
Priming
Prospective Studies
Proton Pump Inhibitors - administration & dosage
RNA, Ribosomal, 23S - genetics
rRNA
rRNA 23S
tailored therapy
Therapy
Treatment Outcome
Yeast
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background We evaluated the efficacy of tailored therapy based on point mutation presence identified with the dual‐priming oligonucleotide (DPO)‐based multiplex polymerase chain reaction (PCR) method compared with concomitant therapy. Materials and methods Subjects were randomly assigned concomitant therapy (amoxicillin 1 g, clarithromycin 500 mg, metronidazole 500 mg, and lansoprazole 30 mg twice/day for 14 days) or tailored therapy (amoxicillin 1 g, clarithromycin 500 mg, and lansoprazole 30 mg twice/day for 14 days in point mutation‐negative subjects; and amoxicillin 1 g, metronidazole 500 mg, and lansoprazole 30 mg twice/day for 14 days in point mutation‐positive subjects). Results A total of 397 and 352 subjects were included in the intention‐to‐treat (ITT) and per‐protocol (PP) analyses, respectively. Point mutations were identified in 25.9% of the subjects. The overall eradication rate was not significantly different between the groups by ITT (86.2% vs 81.6%, P = .132) and PP analyses (90.2% vs 86.5%, P = .179). There was no significant difference in the eradication rates between the groups in both the point mutation‐negative subjects (91.7% vs 87.3%, P = .154) and the point mutation‐positive subjects (71.2% vs 64.7%, P = .312). The eradication rates were significantly lower in the point mutation‐positive subjects than in the point mutation‐negative subjects in both the concomitant and tailored therapy groups. Conclusions Tailored therapy based on point mutation presence identified with the DPO‐based multiplex PCR method was as effective as concomitant therapy. The eradication rates of both therapy regimens were suboptimal in point mutation‐positive subjects.
ISSN:1083-4389
1523-5378
DOI:10.1111/hel.12654